The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30, 2025 and took note of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Coral Laboratories' Board approved unaudited standalone results for Q2 FY26 and H1 FY26 on November 14, 2025. Revenue from operations fell sharply to ₹1,903.48 lakhs in Q2 FY26 from ₹3,222.87 lakhs in Q2 FY25, a drop of about 41% year-on-year; H1 FY26 revenue was ₹3,785.63 lakhs vs ₹6,388.45 lakhs in H1 FY25. Profit after tax declined to ₹582.01 lakhs (Q2) and ₹838.18 lakhs (H1) from ₹637.98 lakhs and ₹1,518.41 lakhs respectively a year earlier, with H1 PAT down roughly 45%. Basic EPS stood at ₹16.29 for the quarter (₹23.46 for H1). The new statutory auditor S C Mehra & Associates LLP issued an unmodified limited review report, noting it took over from previous auditor M. A. Parekh & Associates who retired at the September 26, 2025 AGM.
Sharp revenue and earnings contraction year-on-year is a negative signal for the stock despite a clean audit opinion and the one-time auditor change reflecting normal rotation rather than a red flag. Investors should watch for clarity on the steep sales decline in the coming quarters.